English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/211647
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation

AuthorsMartínez-Torrecuadrada, Jorge Luis; Cifuentes, Gabriela; Lopez-Serra, P.; Sáenz, Pilar; Martínez, Antonio; Casal, J. Ignacio
KeywordsPhage display
Stat activation
FGFR3 mutations
Cancer-cells
Tumor-growth
In-vitro
Antibodies
Affinity
FV
Identification
Issue Date1-Sep-2005
PublisherAmerican Association for Cancer Research
CitationClin Cancer Res 11 (17) 6280-90 (2005)
AbstractPURPOSE:Previous gene expression studies have shown that fibroblast growth factor receptor 3 (FGFR3) is overexpressed in early stages of bladder cancer. To study the potential use of therapeutic antibodies against FGFR3, we have produced a collection of human single-chain Fv (scFv) antibody fragments by using phage display libraries.
EXPERIMENTAL DESIGN:Two "naïve" semi-synthetic human scFv libraries were used to select antibodies against the extracellular domain of FGFR3alpha(IIIc). The reactivity of the selected scFvs with a recombinant FGFR3 was characterized by an enzyme immunoassay and surface plasmon resonance analysis and with RT112 bladder carcinoma cells by a fluorescence-activated cell sorter. The capacity of the selected scFvs to block RT112 cell proliferation was determined.
RESULTS:We have isolated six human scFv antibody fragments directed against FGFR3. These human scFvs specifically bound FGFR3, but not the homologous molecule FGFR1. Biacore analysis was used to determine the affinity constants, which ranged from 12 to 40 nmol/L. Competition analysis showed that the FGF9 ligand was able to block the binding of two scFvs, 3C and 7D, to FGFR3, whereas FGF1 only blocked 7D. Immunoprecipitation and flow cytometric analysis confirmed the specificity of the antibodies to native membrane FGFR3. Two scFvs, 3C and 7D, gave an strong immunofluorescence staining of RT112 cells. Moreover, they recognized equally well wild-type and mutant FGFR3 containing the activating mutation S249C. Furthermore, they blocked proliferation of RT112 cells in a dose- and FGF-dependent manner.
CONCLUSION:Our results suggest that these human anti-FGFR3 scFv antibodies may have potential applications as antitumoral agents in bladder cancer.
Description11 p.-8 fig.-2 tab.
Publisher version (URL)https://doi.org/10.1158/1078-0432.CCR-05-0282
URIhttp://hdl.handle.net/10261/211647
DOI10.1158/1078-0432.CCR-05-0282
ISSN1078-0432
E-ISSN1557-3265
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdfRestringido15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.